Company news
CelLBxHealth plc news in 2026
CelLBxHealth plc's news releases, calls and decks from 2026, newest first.
Q3 Trading Update and FY 2026 Outlook
October 21, 2026
Master Services Agreement with Swiss biotech co
October 21, 2026
New Statement of Work with US-Based Pharma Company
October 14, 2026
Parsortix CTCs used for Brain Cancer detection
August 11, 2026
Parsortix CTCs used for ADC target assessment
August 3, 2026
Q2 and First Half Year Results ended 30 June 2026
July 15, 2026
Directorate change
July 6, 2026
MSA with Global Pharmaceutical Company
May 29, 2026
Collaboration with AdventHealth for two studies
May 18, 2026
Q1 trading update and outlook for 2026
May 11, 2026
Confirmation of Q1 trading update
April 30, 2026
Research Collaboration with The Royal Marsden
April 20, 2026
Board changes - Replacement
April 16, 2026
Aligning Regulatory Approach with Commercial Needs
February 13, 2026
CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results
January 16, 2026
CelLBxHealth PLC Announces Board Changes
January 12, 2026
Calls in 2026
Decks in 2026
- FY2025 Earnings Presentation
Earnings · 29 slides · June 2026